Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iberdomide (CC-220) with dexamethasone ± daratumumab or bortezomib in multiple myeloma (Japan phase 1b/2a)
jRCT2080224873Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2019
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
01
Overview
Phase 2, open-label trial of iberdomide in multiple myeloma (MM) (4 cohorts), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum tolerated dose of iberdomide (CC-220), Safety and tolerability of iberdomide-based regimens and 2 more. Started Sep 2019; status: completed.
02
Drugs
iberdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2080224873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224873.